NeOnc Technologies reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, saying the study met its primary endpoint for six-month progression-free survival. The company cited a PFS-6 of 48.9% against a pre-specified 20% benchmark, with a reported p-value of 0.0047. NeOnc also reported median overall survival of 26.09 months and survival rates of 86.7% at six months, 60.9% at 12 months, and 54.1% at 24 months. The trial enrolled 24 patients in an open-label design, and the update highlighted ongoing treatment in five patients, including one progression-free for about 19 months. Management said it plans to request a Type B meeting with the FDA to discuss a potential registrational development path. The company framed the results as early signal rather than proof, given the small cohort size and the lack of randomization. If regulators and future trials confirm benefit, intranasal delivery could differentiate NEO100 from more invasive approaches, but the key test will be whether the PFS-6 signal holds in larger controlled studies.